Exciting Developments at FOXO Technologies Inc.
FOXO Technologies Inc. (NYSE American: FOXO) is thrilled to share detailed updates regarding its achievements so far in 2024 and the ambitious plans set for the remainder of the year and beyond. As we navigate through this dynamic landscape, our commitment to enhancing human life via innovative health solutions remains unwavering.
A Year of Transformation and Growth
This year has been extraordinarily transformative for FOXO Technologies. Our team has worked diligently, and we believe that the initiatives we have undertaken thus far are setting the stage for robust growth and increased shareholder value.
Since the start of the year, we have focused heavily on commercializing our epigenetic technology. In addition, we have explored strategic acquisition opportunities that promise to boost our revenue growth in the health care sector.
Acquisitions and Their Impact
As we entered the last quarter of 2024, we successfully completed two acquisitions which are expected to generate over $20 million in revenues in 2025. We are optimistic that with these additions to our portfolio, we can substantially increase our revenues to exceed $50 million annually within the next 12 to 24 months.
In the second quarter, we acquired Myrtle Recovery Centers, Inc., a facility dedicated to behavioral health. This center not only supports patients through detox and residential treatment but also provides much-needed outpatient services. With an anticipated annual net revenue of around $3-4 million, we are looking to replicate this successful model in additional locations.
Moreover, we have also brought Scott County Community Hospital, Inc. into the FOXO family, a critical access hospital that reported approximately $18.5 million in revenue last year. This acquisition broadens our service offerings, enabling us to provide a wider array of health services.
Innovative Technologies and Patents
FOXO is pioneering in epigenetic biomarker discovery, with the primary goal of leveraging cutting-edge machine learning technology. In November 2023, we secured a significant patent that utilizes a machine learning model capable of using DNA epigenetic data to predict various health conditions. This innovation stands to revolutionize the way wellness insights are delivered, with applications ranging from consumer health products to wellness monitoring solutions.
Enhancing Personal Health Solutions
The implications of our recent patent are profound. It includes key functionalities such as estimating health metrics and providing reliable biomarkers derived from often incomplete data. By forging the connection between machine learning and epigenetics, we aspire to pioneer personalized healthcare solutions tailored to individual needs.
Committed to Meeting Regulatory Standards
We have also enhanced our financial management team to ensure compliance with SEC reporting requirements. Our focus on regulatory adherence remains strong, as we work to address previously identified deficiencies pertaining to our NYSE listing.
Future Initiatives
As we continue our journey, several key initiatives are on the horizon as we approach the final stretch of 2024. We expect to announce our Annual General Meeting date soon, and our team is heavily focused on meeting the NYSE American continued listing requirements.
Discussions with debtholders are underway to address legacy debts and liabilities. Furthermore, we are in pursuit of new capital inflows, some of which have already been committed, to facilitate expansions and additional acquisitions.
A Bright Future Ahead
Overall, I am incredibly optimistic about the future of FOXO Technologies. The achievements of 2024 have crafted a pathway filled with new opportunities, and we remain dedicated to overcoming challenges that lie ahead. We trust that the backing from our shareholders will fuel our accomplishments and pave the way for a brighter future for all stakeholders involved.
Thank you for your continued support as we strive to innovate and lead in enhancing human health and lifespan.
Sincerely,
Mark White, Interim CEO
Frequently Asked Questions
What are the key goals for FOXO Technologies in 2024?
FOXO aims to enhance its shareholder value through strategic acquisitions and the commercialization of innovative epigenetic technology throughout the year.
How do recent acquisitions impact FOXO's revenue?
The completed acquisitions are expected to generate over $20 million in revenues for 2025, with plans to exceed $50 million annually in the following years.
What advancements in technology is FOXO making?
FOXO has secured a patent involving a machine learning model that uses DNA epigenetic data to enhance health insights and personalized care.
How is FOXO addressing regulatory requirements?
FOXO is enhancing its financial management to ensure compliance with SEC regulations and is actively working to address listing requirements of the NYSE American.
What future initiatives are planned?
FOXO plans to focus on new capital generation and expanding its healthcare service offerings while continuing growth through additional acquisitions.
